L Dahan

Summary

Country: France

Publications

  1. pmc Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
    Laetitia Dahan
    Service d Oncologie Digestive, Pôle Oncologie Spécialités, CHU Timone, Marseille Cedex 5, France
    Gut 59:1527-34. 2010
  2. pmc Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report
    Camille Sibertin-Blanc
    Assistance Publique Hopitaux de Marseille, Service d Oncologie Digestive, Hopital Timone, Universite de la Mediterranee, Marseille, France
    BMC Res Notes 6:471. 2013
  3. pmc Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
    Laetitia Dahan
    Assistance Publique Hopitaux de Marseille, Hopital Timone, Universite de la Mediterranee, Marseille, France
    BMC Cancer 11:496. 2011
  4. doi request reprint Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710
    Laetitia Dahan
    Assistance Publique, Hopitaux de Marseille, Hopital Timone, Universite de la Mediterranee, CHU Timone, Marseille Cedex 5, France
    Endocr Relat Cancer 16:1351-61. 2009
  5. doi request reprint [Postoperative follow-up in patients with colorectal cancers who have undergone curative resection: intensive or conventional follow-up?]
    L Dahan
    Service d Oncologie Digestive, pôle oncologie, spécialités médicales et chirurgicales Timone, Universite de la Mediterranee, CHU Timone, 264 rue Saint Pierre, Marseille, France
    Gastroenterol Clin Biol 32:828-34. 2008
  6. ncbi request reprint BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer
    A Goncalves
    Institut Paoli Calmettes, Marseille, France Centre Antoine Lacassagne, Nice, France APHM La Timone, Marseille, France Hopital Saint Joseph, Marseille, France Centre Hospitalier Bretagne Sud Lorient, Lorient, France Centre Hospitalier Antibes Juan les Pins, Antibes, France Centre Azuréen de Cancérologie, Mougins, France Hôpital Nord APHM, Marseille, France CH Toulon, Toulon, France
    J Clin Oncol 29:4028. 2011
  7. ncbi request reprint Longitudinal analysis of quality of life (QoL) within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA)
    F Bonnetain
    FFCD INSERM U866, Dijon, France CHRU Marseille AP HM, Marseille, France Hôpital Ambroise Paré AP HP, Boulogne, France Centre de Lutte contre le Cancer Val d aurelle, Montpellier, France Hopitaux Nord de Marseille AP HM, Marseille, France Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France CHRU, Lille, France
    J Clin Oncol 27:e17544. 2009
  8. ncbi request reprint LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301)
    E Mitry
    Ambroise Paré, APHP, Boulogne, France La Timone, AP HM, Marseille, France Centre Val d Aurelle, Montpellier, France FFCD, Dijon, France Hôpital Nord, AP HM, Marseille, France Centre Eugène Marquis, Rennes, France Hopital Claude Hurriez, Lille, France CHU, Grenoble, France Fédération Francophone de Cancérologie Digestive
    J Clin Oncol 26:4513. 2008
  9. ncbi request reprint Pancreatic cancer and pancreaticoduodenectomy in elderly patient: morbidity and mortality are increased. Is it the real life?
    Mehdi Ouaissi
    Pôle d oncologie et spécialités Médico chirurgicales, Service de Chirurgie Digestive et Oncologique, Hopital Timone, Marseille, France
    Hepatogastroenterology 55:2242-6. 2008
  10. ncbi request reprint Experience of two trauma-centers with pancreatic injuries requiring immediate surgery
    Mehdi Ouaissi
    Service de Chirurgie Digestive et Oncologique, Pôle d Oncologie et de Spécialité Médicale et Chirurgicale Hôpital Timone, Marseille, France
    Hepatogastroenterology 55:817-20. 2008

Collaborators

Detail Information

Publications26

  1. pmc Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
    Laetitia Dahan
    Service d Oncologie Digestive, Pôle Oncologie Spécialités, CHU Timone, Marseille Cedex 5, France
    Gut 59:1527-34. 2010
    ..The first strategic phase III trial comparing LV5FU2-CDDP followed by gemcitabine versus gemcitabine followed by LV5FU2-CDDP was conducted...
  2. pmc Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report
    Camille Sibertin-Blanc
    Assistance Publique Hopitaux de Marseille, Service d Oncologie Digestive, Hopital Timone, Universite de la Mediterranee, Marseille, France
    BMC Res Notes 6:471. 2013
    ..Novel therapeutic agents are currently being investigated for neuroendocrine tumour treatment...
  3. pmc Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
    Laetitia Dahan
    Assistance Publique Hopitaux de Marseille, Hopital Timone, Universite de la Mediterranee, Marseille, France
    BMC Cancer 11:496. 2011
    ....
  4. doi request reprint Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710
    Laetitia Dahan
    Assistance Publique, Hopitaux de Marseille, Hopital Timone, Universite de la Mediterranee, CHU Timone, Marseille Cedex 5, France
    Endocr Relat Cancer 16:1351-61. 2009
    ..Despite a trend in favor of IFN, there was no difference in PFS and OS in advanced metastatic carcinoid tumors and therapeutic effect of both treatments was mild...
  5. doi request reprint [Postoperative follow-up in patients with colorectal cancers who have undergone curative resection: intensive or conventional follow-up?]
    L Dahan
    Service d Oncologie Digestive, pôle oncologie, spécialités médicales et chirurgicales Timone, Universite de la Mediterranee, CHU Timone, 264 rue Saint Pierre, Marseille, France
    Gastroenterol Clin Biol 32:828-34. 2008
    ..To update recommendations for surveillance of colorectal cancer, larger prospective randomized studies are required...
  6. ncbi request reprint BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer
    A Goncalves
    Institut Paoli Calmettes, Marseille, France Centre Antoine Lacassagne, Nice, France APHM La Timone, Marseille, France Hopital Saint Joseph, Marseille, France Centre Hospitalier Bretagne Sud Lorient, Lorient, France Centre Hospitalier Antibes Juan les Pins, Antibes, France Centre Azuréen de Cancérologie, Mougins, France Hôpital Nord APHM, Marseille, France CH Toulon, Toulon, France
    J Clin Oncol 29:4028. 2011
    ..The BAYPAN study was conducted to compare G+S versus G + placebo (P) in APC pts...
  7. ncbi request reprint Longitudinal analysis of quality of life (QoL) within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA)
    F Bonnetain
    FFCD INSERM U866, Dijon, France CHRU Marseille AP HM, Marseille, France Hôpital Ambroise Paré AP HP, Boulogne, France Centre de Lutte contre le Cancer Val d aurelle, Montpellier, France Hopitaux Nord de Marseille AP HM, Marseille, France Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France CHRU, Lille, France
    J Clin Oncol 27:e17544. 2009
    ..To longitudinally compare QoL according to treatment sequence we have explore definitions of time until definitive deterioration (TUDD) of QoL scores according to minimal clinically important difference (MCID) cut off...
  8. ncbi request reprint LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301)
    E Mitry
    Ambroise Paré, APHP, Boulogne, France La Timone, AP HM, Marseille, France Centre Val d Aurelle, Montpellier, France FFCD, Dijon, France Hôpital Nord, AP HM, Marseille, France Centre Eugène Marquis, Rennes, France Hopital Claude Hurriez, Lille, France CHU, Grenoble, France Fédération Francophone de Cancérologie Digestive
    J Clin Oncol 26:4513. 2008
    ..This randomized multicenter phase III trial compared LV5FU2-P followed by gemcitabine in arm A versus gemcitabine followed by LV5FU2-P in arm B to evaluate the best sequence...
  9. ncbi request reprint Pancreatic cancer and pancreaticoduodenectomy in elderly patient: morbidity and mortality are increased. Is it the real life?
    Mehdi Ouaissi
    Pôle d oncologie et spécialités Médico chirurgicales, Service de Chirurgie Digestive et Oncologique, Hopital Timone, Marseille, France
    Hepatogastroenterology 55:2242-6. 2008
    ..The aim of this study was to compare post-operative outcomes of two groups of patients aged more or less than 70 years old..
  10. ncbi request reprint Experience of two trauma-centers with pancreatic injuries requiring immediate surgery
    Mehdi Ouaissi
    Service de Chirurgie Digestive et Oncologique, Pôle d Oncologie et de Spécialité Médicale et Chirurgicale Hôpital Timone, Marseille, France
    Hepatogastroenterology 55:817-20. 2008
    ..The aim of the present study was to evaluate a simplified approach of management of pancreatic trauma injuries requiring immediate surgery consisting of either drainage in complex situation or pancreatectomy in the other cases...
  11. doi request reprint High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas
    Mehdi Ouaissi
    Service de Chirurgie Digestive et Oncologique, Pôle d Oncologie et Spécialité Médico Chirurgicales, Assistance Pubique Hôpitaux de Marseille, Hopital Timone, 264 rue Saint Pierre, Marseille 13000, France
    Ann Surg Oncol 15:2318-28. 2008
    ..The aim of the present study was to evaluate the expression levels of members of class I (HDAC1, 2,, 3), class II (HDAC4, 5, 6, and 7), and class III (SIRT1, 2, 3, 4, 5, and 6) in a set of surgically resected pancreatic tissues...
  12. ncbi request reprint [Palliative endoscopic treatments for esophageal cancers]
    Laetitia Dahan
    Service d Hépatogastroentérologie et d Oncologie Digestive, CHU Timone, 264 rue Saint Pierre, 13385 Marseille Cedex 5
    Gastroenterol Clin Biol 30:253-61. 2006
    ..Other techniques like bipolar electrocoagulation have restricted indications especially for circonferential stenosis of cervical esophagus. However, the main problem remains the dysphagia relapse after treatment...
  13. ncbi request reprint Pemetrexed in pancreatic cancer
    Jean Francois Seitz
    C H U la Timone and Université de la Méditerranée Marseille, France
    Oncology (Williston Park) 18:43-7. 2004
    ..While an increase in response and time to progression was reported for the gemcitabine/pemetrexed combination, there were no significant differences in survival between treatment arms...
  14. ncbi request reprint Esophagus cancer
    Jean Francois Seitz
    Service d Hépato Gastroentérologie et Oncologie Digestive, CHU Timone, Marseille
    Gastroenterol Clin Biol 30:2S5-2S15. 2006
  15. doi request reprint BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
    A Goncalves
    Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France
    Ann Oncol 23:2799-805. 2012
    ..The BAYPAN study was a multicentric, placebo-controlled, double-blind, randomized phase III trial comparing gemcitabine/sorafenib and gemcitabine/placebo in the treatment of APC...
  16. doi request reprint Indications and outcome of salvage surgery for oesophageal cancer
    Xavier Benoit D'Journo
    Department of Thoracic Surgery, Ste Marguerite University Hospital, Marseille, France
    Eur J Cardiothorac Surg 33:1117-23. 2008
    ..The aim of this study was to assess the benefit/risk ratio of surgery in such context...
  17. ncbi request reprint Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients
    Laetitia Dahan
    Service d Hepatogastroenterologie, unité d oncologie digestive, CHU Timone, Marseille, France
    Gastroenterol Clin Biol 29:11-5. 2005
    ..The aim of this retrospective and multicentric study was to determine the tolerance of a postoperative chemoradiotherapy regimen using LV5FU2 instead of the Mayo Clinic regimen...
  18. ncbi request reprint Impact of first-line and second-line PFS definitions within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA)
    L Dahan
    CHU Timone, Marseille, France FFCD, Dijon, France Hôpital Ambroise Paré, Boulogne, France Val d Aurelle, Montpellier, France Hôpital Nord, Marseille, France Centre Eugène Marquis, Rennes, France CHU Lille, Lille, France
    J Clin Oncol 27:e15583. 2009
    ..The aim of this ancillary study was to investigate definitions of 1st and 2nd line PFS and their impacts on results...
  19. ncbi request reprint Anticipating gemcitabine-related severe/lethal toxicities: A feasibility study
    L Padovani
    La Timone University Hospital, Marseille, France Aix Marseille University, Marseille, France
    J Clin Oncol 26:14652. 2008
    ..The aim of this work was to evaluate the feasibility and relevance of screening CDA status in patients undergoing gemcitabine-based therapy...
  20. ncbi request reprint Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX)
    G Lledo
    Hôpital Privá Jean Mermoz, Lyon, France University Hospital, Rouen, France La Timone University Hospital, Marseille, France Institut Sainte Catherine, Avignon, France Centre François Baclesse, Caen, France Clinique Victor Hugo, Le Mans, France Hopital Robert Boulin, Libourne, France Institut Jean Godinot, Reims, France GERCOR, Paris, France Hôpital Saint Antoine, Paris, France
    J Clin Oncol 29:8. 2011
    ..Cetuximab (C) has demonstrated synergism with both radiotherapy (RT) and platinum-based chemotherapy. ERaFOX trial was evaluating the safety and efficacy of the addition of C to CRT with FOLFOX...
  21. ncbi request reprint FOLFIRI followed by radiochemotherapy and surgery in locally advanced gastric cancer: FFCD 0308 phase II trial
    P Michel
    University Hospital, Rouen, France Hopital Pasteur, Colmar, France Centre Leon Berard, Lyon, France La Timone, Marseille University Hospital, Marseille, France Clermont Ferrand University Hospital, Clermont Ferrand, France Lyon University Hospital, Lyon, France Creteil University Hospital, Creteil, France Centre Hospitalier de Beauvais, Beauvais, France Institut Paoli Calmettes, Marseille, France University Hospital of Toulouse, Toulouse, France Lille University Hospital, Lille, France Institut Daniel Holland, Grenoble, France Caen University Hospital, Caen, France Centre François Baclesse, Caen, France Besançon University Hospital, Besancon, France Rouen University Hospital, Rouen, France Biostatistic Unit, Fédération Francophone de Cancérologie Digestive, Dijon, France Hôpital Cochin, Paris, France Fédération Francophone de Cancérologie Digestive
    J Clin Oncol 29:4108. 2011
    ..The aim of this trial was to assess the feasibility of complete treatment (CT+CTRT+surgery) with a CT regimen efficient and well tolerated in metastatic phase...
  22. ncbi request reprint Extracapsular lymph node involvement is a negative prognostic factor after neoadjuvant chemoradiotherapy in locally advanced esophageal cancer
    Xavier Benoit D'Journo
    Department of Thoracic Surgery and Diseases of the Esophagus, Sainte Marguerite University Hospital, Marseille, France
    J Thorac Oncol 4:534-9. 2009
    ..To assess prognosis depending on whether lymph node involvement (LNI) is intracapsular or with extracapsular breakthrough in patients with a locally advanced esophageal cancer treated with neoadjuvant chemoradiation and surgery...
  23. ncbi request reprint Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency
    Joseph Ciccolini
    Clinical Pharmacokinetics Department, La Timone University Hospital, Marseille, France
    Cancer Chemother Pharmacol 58:272-5. 2006
    ..The case reported here warrants therefore systematic detection of patients at risk, including when oral capecitabine is scheduled...
  24. doi request reprint Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies
    Joseph Ciccolini
    MD, Medical Oncology Unit, La Timone University Hospital, 205 Rue St Pierre, 13385, Marseille, Cedex 05, France
    J Clin Oncol 28:160-5. 2010
    ..Particularly, this study demonstrates that CDA deficiency, found in 7% of adult patients, is associated with a maximum risk of developing early severe toxicities with gemcitabine...
  25. ncbi request reprint A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy
    Joseph Ciccolini
    Clinical Pharmacokinetics Department, La Timone University Hospital, Marseille, France
    Ther Drug Monit 28:678-85. 2006
    ..Finally, the simplified methodology presented here proved to be a low cost and rapid way to identify routinely patients at risk of toxicity with 5-FU or capecitabine...
  26. pmc Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines
    Laetitia Dahan
    UMR INSERM 911, Centre de Recherche en Oncologie biologique et Oncopharmacologie, Faculte de Pharmacie, Aix Marseille Universite, Marseille, France
    Br J Pharmacol 158:610-20. 2009
    ..K-Ras mutation is known to affect redox homeostasis. Here we evaluated how the efficacy of oxaliplatin alone or combined with cetuximab varied according to the Ras mutation and redox status in a panel of colorectal tumour cell lines...